Please use this identifier to cite or link to this item: https://open.uns.ac.rs/handle/123456789/12163
DC FieldValueLanguage
dc.contributor.authorNissan A.en
dc.contributor.authorProtić, Mlađanen
dc.contributor.authorBilchik A.en
dc.contributor.authorHoward R.en
dc.contributor.authorPeoples G.en
dc.contributor.authorStojadinović, Aleksandraen
dc.date.accessioned2020-03-03T14:47:26Z-
dc.date.available2020-03-03T14:47:26Z-
dc.date.issued2012-09-01en
dc.identifier.issn34932en
dc.identifier.urihttps://open.uns.ac.rs/handle/123456789/12163-
dc.description.abstractObjective: Our randomized controlled trial previously demonstrated improved staging accuracy with targeted nodal assessment and ultrastaging (TNA-us) in colon cancer (CC). Our objective was to test the hypothesis that TNA-us improves disease-free survival (DFS) in CC. Methods: In this randomized trial, targeted nodal assessment and ultrastaging resulted in enhanced lymph node diagnostic yield associated with improved staging accuracy, which was further associated with improved disease-free survival in early colon cancer. Results: Clinical parameters of the control (n = 94) and TNA-us (n = 98) groups were comparable. Median (interquartile range) lymph node yield was higher in the TNA-us arm: 16 (12-22) versus 13 (10-18); P = 0.002. Median follow-up was 46 (29-70) months. Overall 5-year DFS was 61% in the control arm and 71% in the TNA-us arm (P = 0.11). Clinical parameters of node-negative patients in the control (n = 51) and TNA-us (n = 55) groups were comparable. Lymph node yield was higher in the TNA-us arm: 15 (12-21) versus 13 (8-18); P = 0.03. Five-year DFS differed significantly between groups with node-negative CC (control 71% vs TNA-us 86%; P = 0.04). Survival among stage II CC alone was higher in the TNA-us group, 83% versus 65%; P = 0.03. Adjuvant chemotherapy use was nearly identical between groups. TNA-us stratified CC prognosis; DFS differed significantly between ultrastaged and conventionally staged node-negative patients [control pN0 72% vs TNA-us pN0(i-) 87%; P = 0.03]. Survival varied according to lymph node yield in patients with node-negative CC [5-year DFS: <12 lymph nodes = 57% vs 12+ lymph nodes = 85%; P = 0.011] but not in stage III CC. Conclusions: TNA-us is associated with improved nodal diagnostic yield and enhanced staging accuracy (stage migration), which is further associated with improved DFS in early CC. © 2012 Lippincott Williams & Wilkins.en
dc.relation.ispartofAnnals of Surgeryen
dc.titleUnited states military cancer institute clinical trials group (USMCI GI-01) randomized controlled trial comparing targeted nodal assessment and ultrastaging with standard pathological evaluation for colon canceren
dc.typeConference Paperen
dc.identifier.doi10.1097/SLA.0b013e31826571c8en
dc.identifier.pmid256en
dc.identifier.scopus2-s2.0-84865470694en
dc.identifier.urlhttps://api.elsevier.com/content/abstract/scopus_id/84865470694en
dc.relation.lastpage427en
dc.relation.firstpage412en
dc.relation.issue3en
dc.relation.volume256en
item.grantfulltextnone-
item.fulltextNo Fulltext-
crisitem.author.deptKatedra za hirurgiju-
crisitem.author.deptKatedra za pedijatriju-
crisitem.author.parentorgMedicinski fakultet-
crisitem.author.parentorgMedicinski fakultet-
Appears in Collections:MDF Publikacije/Publications
Show simple item record

SCOPUSTM   
Citations

25
checked on May 10, 2024

Page view(s)

74
Last Week
26
Last month
0
checked on May 10, 2024

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.